2025-10-20		Reproducibility by Design: Data and Workflows for Pharmacokinetic Digital Twins Michelle Elias and Matthias König COMBINE2025 - Computational Modeling in Biology
2025-10-16		Reproducibility by Design: Data and Workflows for Pharmacokinetic Digital Twins Michelle Elias and Matthias König RDA 25th Plenary Meeting [part of International Data Week 2025] - Towards reproducible and transparent computational modelling in health and biomedical research
2025-10-14		Reproducibility of a Digital Twin of Glimepiride for Personalized and Stratified Diabetes Treatment Michelle Elias and Matthias König 18th International CellML Workshop
2025-09-10		Reproducibility of a Digital Twin of Glimepiride for Personalized and Stratified Diabetes Treatment Michelle Elias and Matthias König Institute for Theoretical Biology, Institute Seminar
2025-06-16		Reproducible Digital Twins for Studying the Effect of Disease on Pharmacokinetics Matthias König 17th International Conference on Systems Biology of Human Disease (SBHD2025)
2025-04-24		Digital Twins of the Liver in Pharmacokinetics Matthias König Camo Seminar, KIT Institute of Biomedical Engineering, Computational Cardiac Modeling
2025-04-17		Reproducible Digital Twins in Pharmacokinetics Matthias König 9th Disease Maps Community Meeting (DMCM2025)
2025-02-05		Reproducible digital twins for personalized drug pharmacokinetics Matthias König Disease Maps Meeting
2025-02-05		Reproducible digital twins for personalized liver function assessment Matthias König University of Darmstadt, Institute for Mechanics, Institute Seminar
2024-09-02		Reproducible digital twins for personalized liver function assessment Matthias König COMBINE 2024 Stuttgart
2023-10-10		Reproducible digital twins for personalized liver function assessment Matthias König e:Med Meeting 2023 on Systems Medicine
2023-10-10		Reproducible digital twins for personalized liver function assessment Matthias König Institute for Theoretical Biology Meeting
2023-09-22		Studying the impact of drug metabolism on the liver tissue: An integrated biomechanical modeling approach Matthias König, Steffen Gerhäusser, Luis Mandl, Lena Lambers, Uta Dahmen, Hans-Michael Tautenhahn, Tim Ricken X International Conference on Computational Bioengineering
2023-09-01		Digital twins for liver function & metabolic phenotyping Matthias König AstraZeneca seminar
2023-06-19		Advancing Liver Function Assessment: Personalized and Stratified Approaches with Standardized Computational Models and Data Matthias König Workshop on Computational Models in Biology and Medicine 2023
2023-05-22		Digital twins for liver function & metabolic phenotyping Matthias König Workshop on Modelling in Biology and Medicine
2022-07-22		Developing computational models with SBML - sbmlutils & cy3sbml Matthias König CRBM Network Modeling Virtual Symposium

2025-07-07		A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of Lixisenatide Olivia Yau2, Matthias König1 1Humboldt-Universität zu Berlin, Institute for Theoretical Biology, Berlin, Germany, 2University of Toronto, Dept. of Pharmacology and Toxicology, Toronto, Canada HIC conference 2025, Humboldt Internship Program Day, Berlin, 7 July 2025 This project leverages an open pharmacokinetics database, along with established data curation and model simulation protocols, to develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for the GLP-1 receptor agonist lixisenatide. Since type 2 diabetes mellitus (T2DM) is often accompanied by liver and renal impairments, obesity, and cardiovascular disease, this study aims to assess how these factors influence drug behavior. By developing a PBPK/PD model, we aim to establish a tool to support personalized medicine of T2DM management. Keywords: pharmacokinetics, pharmacodynamics, lixisenatide, GLP-1 agonists,
2025-07-07		A Physiologically Based Pharmacokinetic Model of Dulaglutide Kim Minjun2, Matthias König1 1Humboldt-Universität zu Berlin, Institute for Theoretical Biology, Berlin, Germany, 2National University of Singapore, Singapore HIC conference 2025, Humboldt Internship Program Day, Berlin, 7 July 2025 This Humboldt Internship project develops a physiologically based pharmacokinetic (PBPK) model of dulaglutide, a GLP-1 receptor agonist. The objective of this project is to enhance our understanding of dose-dependency of systemic exposure to dulaglutide, and the different underlying causes of intraindividual variability in efficacy of diabetes treatment with dulaglutide. Keywords: pharmacokinetics, pharmacodynamics, dulaglutide, GLP-1 agonists,
2025-07-07		A Physiologically-Based Pharmacokinetic and Pharmacodynamic Model of Liraglutide Isabella Tan2, Matthias König1 1Humboldt-Universität zu Berlin, Institute for Theoretical Biology, Berlin, Germany, 2University of Toronto, Dept. Pharmacology & Biomedical Toxicology, Toronto, Canada HIC conference 2025, Humboldt Internship Program Day, Berlin, 7 July 2025 Liraglutide, known commercially as Victoza(R), is a Glucagon-Like Peptide 1 (GLP-1) agonist used in the treatment of type 2 diabetes and obesity. The objective of this study is to develop a physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) model of liraglutide. Through this study, the aim is to develop a better understanding of liraglutide pharmacology and improve personalized medicine approaches. Keywords: pharmacokinetics, pharmacodynamics, liraglutide, GLP-1 agonists,
2024-11-05		Multi-scale Modelling of Liver Perfusion and Function Matthias König1 1Humboldt-Universität zu Berlin, Faculty of Life Science, Institute for Biology, Systems Medicine of the Liver, Berlin, Germany Qualiperf 2 Defense, 5 November 2024 Hypothesis: Computational modelling of 3D spatial heterogeneity of perfusion & function will significantly improve functional assessment of the liver. Contribution: A multi-scale model of liver 3D perfusion & function heterogeneity. Keywords: pharmacokinetics, pharmacodynamics, digital twin, liver, perfusion, function,
2024-11-05		Data Management Project Matthias König1, Hans-Michael Tautenhahn2 1Humboldt-Universität zu Berlin, Faculty of Life Science, Institute for Biology, Systems Medicine of the Liver, Berlin, Germany 2Department of Visceral, Transplantation, Thoracic and Vascular Surgery, Universitätsklinikum Leipzig Qualiperf 2 Defense, 5 November 2024 Central data management project. Keywords: data management, FAIR,
2024-07-18		PK-LLM : Large Language Model (LLM) for Pharmacokinetic (PK) Data Curation Prerna Parakkat2, Matthias König1 1Humboldt-University of Berlin, Institute for Theoretical Biology, Berlin, Germany, 2Vellore Institute of Technology, Chennai, India HIC conference 2024, Humboldt Internship Program Day, Berlin, 18 July 2024 Our group has developed PK-DB, an open pharmacokinetics database from clinical and preclinical research. The aim of this Humboldt Internship project is to use Large Language Models (LLM) to support effective data curation for PK-DB from scientific pharmacokinetic literature. Keywords: LLM, large language models, pharmacometrics, pharmacokinetics,
2024-07-18		Canagliflozin Vera Tereshchuk1, Matthias König2 1Moscow Institute of Physics and Technology, 2Humboldt-University of Berlin, Institute for Theoretical Biology, Berlin, Germany HIC conference 2024, Humboldt Internship Program Day, Berlin, 18 July 2024 In this project, we are developing a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model of the SGLT2 inhibitor canagliflozin. The aim is to improve our understanding of intra-individual variability in diabetes treatment with SGLT2 inhibitors, e.g. differences in hepatorenal function. Keywords: canagliflozin, pharmacometrics,
2024-07-18		A physiologically based pharmacokinetic model of morphine Deepa Maheshvare M.2, Rohini Chakraborty2, Rohit Chakraborty2, Matthias König1 2Humboldt-University of Berlin, Institute for Theoretical Biology, Berlin, Germany, 2Indian Institute of Science, Bengaluru, India HIC conference 2024, Humboldt Internship Program Day, Berlin, 18 July 2024 This Humboldt Internship project develops a physiologically based pharmacokinetic (PBPK) model of the pain medication morphine. The objective is to enhance our understanding of how underlying causes of intraindividual variability in morphine treatment, e.g., differences in absorption rates or hepatorenal function. Keywords: morphine, pharmacometrics,
2024-06-26		Captopril in Focus: Establishing an Open Pharmacokinetic Dataset and PBPK Modeling Mariia Myshkina1, Matthias König1 1Humboldt-University of Berlin, Institute for Theoretical Biology, Berlin, Germany PAGE2024 - Population Approach Group Europe, Rome, 26-28 June 2024 Introduction: Angiotensin-converting enzyme (ACE) inhibitors, such as captopril, are widely prescribed for the treatment of hypertension and heart failure. Captopril, the first ACE inhibitor developed in the 1980s, is primarily taken orally and is rapidly absorbed, reaching peak plasma concentrations within an hour. Its half-life is approximately 2 hours, but several factors, including renal function, heart disease, age and sex, can affect its pharmacokinetics. Despite the widespread use of captopril, comprehensive pharmacokinetic data have been lacking. Our group has developed PK-DB (https://pk-db.com) [1], an open database containing high-quality pharmacokinetic data from clinical and preclinical research. PK-DB includes patient cohort characteristics, interventions, concentration-time profiles, and kinetic parameters, with the ability to automatically calculate pharmacokinetic parameters using non-compartmental methods. Objectives: The objectives of this study were to curate and analyze captopril pharmacokinetic data, expand the PK-DB, develop a whole-body physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model of captopril in accordance with FAIR principles [2], and improve understanding of the intra-individual variability in captopril pharmacokinetics influenced by factors such as age, sex, renal and cardiac function. Methods: Over 600 publications on captopril pharmacokinetics were reviewed through a systematic literature search, with a subset selected for data curation in PK-DB. The PBPK model was developed using a compartmental approach and encoded in Systems Biology Markup Language (SBML) [3] for accessibility and reproducibility. Results: A comprehensive set of captopril pharmacokinetic data was generated from 15 clinical studies in healthy volunteers and patients with renal impairment, heart failure and hypertension. The PBPK model includes four major compartments (blood, intestine, liver, kidney) and describes absorption, distribution, metabolism and excretion. It successfully represents the pharmacokinetic profile of captopril in different age groups, showing minimal age-related differences in unchanged drug concentration. Heart failure did not significantly affect maximum plasma concentration or area under the curve (AUC), but renal function strongly influenced captopril elimination. We present this data set and open PBPK model of captopril as a valuable resource for further research. Conclusions: This study successfully establishes a freely accessible, comprehensive dataset and an open PBPK model of captopril, enhancing our understanding of its pharmacokinetic behavior across different patient groups. Our findings emphasize the significance of renal function in captopril elimination and provide a valuable resource for personalized medicine approaches in hypertension and heart failure treatment. References: [1] Grzegorzewski, J. et al. 2021. PK-DB: pharmacokinetics database for individualized and stratified computational modeling. Nucleic Acids Research. 49, D1 (Jan. 2021), D1358–D1364. DOI:https://doi.org/10.1093/nar/gkaa990. [2] Wilkinson, M.D. et al. 2016. The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data. 3, (Mar. 2016), 160018. DOI:https://doi.org/10.1038/sdata.2016.18. [3] Keating, SM. et al, SBML Level 3: an extensible format for the exchange and reuse of biological models. Mol Syst Biol. 2020 Aug;16(8):e9110. doi: 10.15252/msb.20199110. Keywords: captopril, pharmacometrics,
2010-06-01		Blood glucose control by the human hepatocyte Matthias König1, Sascha Bulik1, Hermann-Georg Holzhütter1 1Charité University Medicine Berlin, Insitute of Biochemistry, Berlin, Germany Spetses 2010 Introduction: Plasma glucose levels are tightly controlled to ensure a constant glucose supply and to avoid toxic effects of hyperglycemic conditions. The liver is the central organ of glucose homeostasis and the main glucose producer (hepatic glucose production HGP), but also utilizes glucose for biosyntheses and storage in fatty acids (hepatic glucose utilization HGU). Results: We present the first detailed kinetic model of the human hepatocyte glucose metabolism [Fig.1] which comprises allosteric regulation as well as hormonal regulation by insulin and glucagon via inter-convertible enzymes [Fig.2]. The model reproduces fundamental features of hepatic glucose metabolism like glucose dependent switch between HGP and HGU [Fig.3] observed changes in glucose homeostasis in diabetes II [Fig.4] dependency of HGP on gluconeogenic substrates (lactate). Outlook: Possible future applications of the model are analysis of hepatic effects of various diabetic treatments simulations of the influence of temporary changes in the gene expression on the glucose homeostasis (for example circadian rhythms of gene expression). Keywords: glucose, modelling,